| P/E (FY) | — | Sales (TTM) | €0 |
| Earnings (TTM) | -€25.0M | ROE | −138.61% |
| Net Margin | — | ROIC | −52.33% |
| Debt / Equity | 3.98 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Carvolix SA is a medical technology company that develops and markets minimally invasive devices for urology and structural heart conditions in France. Its products include Artus, an implantable electro-mechanical artificial sphincter for urinary incontinence, and the Kalios and Epygon implants for mitral insufficiency, along with Kardiozis technology for abdominal aortic aneurysm. Formerly known as Affluent Medical SA, the company was founded in 2011 and is headquartered in Aix-en-Provence, France.
No price history for CVX.PA — it is outside the redistributable backbone (BYOK data required), so price statistics are unavailable.
No return history for CVX.PA, so risk analytics are unavailable.
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OABI | OmniAb, Inc. | $285.6M | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $282.5M | — |
| SGHT | Sight Sciences, Inc. | $288.4M | — |
| FBIO | Fortress Biotech, Inc. | $279.6M | — |
| IRD | Opus Genetics, Inc. | $277.6M | — |
| OSUR | ORASURE TECHNOLOGIES INC | $276.8M | — |
| PSTV | PLUS THERAPEUTICS, INC. | $292.5M | — |
| RMTI | ROCKWELL MEDICAL, INC. | $275.9M | — |
| AGEN | AGENUS INC | $274.8M | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $273.0M | — |
| FATE | FATE THERAPEUTICS INC | $270.4M |
| — |
| FHTX | Foghorn Therapeutics Inc. | $301.2M | — |
